These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20942630)

  • 1. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M; Fidler MJ; Bonomi PD
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
    Pennell NA
    Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
    Yoshida T; Zhang G; Haura EB
    Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
    Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.
    Gorden KJ; Mesbah P; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):245-9. PubMed ID: 21733906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
    Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
    Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR FISH versus mutation: different tests, different end-points.
    Cappuzzo F
    Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.